Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Title
Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study
Authors
박용수
Keywords
Lobeglitazone; Thiazolidinediones; Clinical trial; Randomised trial
Issue Date
2015-07
Publisher
Elsevier
Citation
Diabetes Research and Clinical Practice, v. 110, NO 3, Page. 27-30
Abstract
We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
URI
http://www.sciencedirect.com/science/article/pii/S0168822715003824http://hdl.handle.net/20.500.11754/26253
ISSN
0168-8227; 1872-8227
DOI
http://dx.doi.org/10.1016/j.diabres.2015.09.009
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE